UBS Global Research initiated coverage on Alibaba Health Information Technology (00241) with a "buy" rating and a target price of HK$26.
The research house likes Ali Health for its potential to reshape the traditional pharmaceutical distribution model. It added that Ali Health could leverage off large e-commerce customers and merchants on the Taobao and Tmall platforms, and also other user flow on DingTalk and other OTO platforms such as Koubei.
UBS said current stock price mainly reflects the effect of COVID-19, but not fully the sector's long-growth potential; UBS forecast a 40% revenue CAGR over 2019-25 for sector leaders.